

Eva Ramos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/378442/publications.pdf>

Version: 2024-02-01

43
papers

967
citations

430874

18
h-index

454955

30
g-index

46
all docs

46
docs citations

46
times ranked

1851
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?. Cellular and Molecular Neurobiology, 2022, 42, 489-500.	3.3	25
2	A BLENDED LEARNING EXPERIENCE IN THE TOXICOLOGY LABORATORY. INTED Proceedings, 2022, , .	0.0	0
3	Synthesis and Pharmacological Evaluation of New <i>N</i> -Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout. Journal of Medicinal Chemistry, 2022, 65, 6250-6260.	6.4	10
4	In Silico Prediction of the Toxic Potential of Neuroprotective Bifunctional Molecules Based on Chiral <i>N</i> -Propargyl-1,2-amino Alcohol Derivatives. Chemical Research in Toxicology, 2021, 34, 1245-1249.	3.3	2
5	Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 TjE	2.5	9
6	The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy. Antioxidants, 2021, 10, 1152.	5.1	19
7	Melatonin Reduces NLRP3 Inflammasome Activation by Increasing $\hat{I} \pm 7$ nAChR-Mediated Autophagic Flux. Antioxidants, 2020, 9, 1299.	5.1	26
8	In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases. ACS Chemical Neuroscience, 2020, 11, 3793-3801.	3.5	7
9	Melatonin's efficacy in stroke patients; a matter of dose? A systematic review. Toxicology and Applied Pharmacology, 2020, 392, 114933.	2.8	15
10	Melatonin and neurodegeneration: From neurotoxic environment to cell resilience. Advances in Molecular Toxicology, 2020, 13, 69-108.	0.4	4
11	Impact of melatonin effects on toxicology of vesicant chemical warfare agents: When science meets reality. Melatonin Research, 2020, 3, 101-119.	1.1	2
12	Highlights of ASS234: a novel and promising therapeutic agent for Alzheimer's disease therapy. Neural Regeneration Research, 2020, 15, 30.	3.0	10
13	Potential of Melatonin as Adjuvant Therapy of Oral Cancer in the Era of Epigenomics. Cancers, 2019, 11, 1712.	3.7	21
14	QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer's Disease Therapy. Molecules, 2019, 24, 1503.	3.8	12
15	New flavonoid <i>N,N</i> -dibenzyl(<i>N</i> -methyl)amine hybrids: Multi-target-directed agents for Alzheimer's disease endowed with neurogenic properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 712-727.	5.2	27
16	Analysis of gene expression profiles of CR80, a neuroprotective 1,8-Naphthyridine. Future Medicinal Chemistry, 2018, 10, 1289-1300.	2.3	4
17	Melatonin: A hypothesis for Kawasaki disease treatment. Medical Hypotheses, 2018, 119, 6-10.	1.5	3
18	Neuroinflammation Signaling Modulated by ASS234, a Multitarget Small Molecule for Alzheimer's Disease Therapy. ACS Chemical Neuroscience, 2018, 9, 2880-2885.	3.5	14

#	ARTICLE	IF	CITATIONS
19	In silico assessment of the metabolism and its safety significance of multitarget propargylamine <sc>ASS</sc>234. CNS Neuroscience and Therapeutics, 2018, 24, 981-983.	3.9	2
20	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 156, 534-553.	5.5	38
21	Modulation of Heat Shock Response Proteins by ASS234, Targeted for Neurodegenerative Diseases Therapy. Chemical Research in Toxicology, 2018, 31, 839-842.	3.3	16
22	Ischemic brain injury: New insights on the protective role of melatonin. Free Radical Biology and Medicine, 2017, 104, 32-53.	2.9	80
23	Neuroprotective effects of Eâ€PodoFavalinâ€15999 (AtremorineÂ®). CNS Neuroscience and Therapeutics, 2017, 23, 450-452.	3.9	15
24	Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration. Future Medicinal Chemistry, 2017, 9, 765-780.	2.3	21
25	Oxidative stress and gene expression profiling of cell death pathways in alpha-cypermethrin-treated SH-SY5Y cells. Archives of Toxicology, 2017, 91, 2151-2164.	4.2	42
26	Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. Frontiers in Aging Neuroscience, 2016, 8, 281.	3.4	7
27	Mycotoxins modify the barrier function of Caco-2 cells through differential gene expression of specific claudin isoforms: Protective effect of illite mineral clay. Toxicology, 2016, 353-354, 21-33.	4.2	80
28	Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices. NeuroToxicology, 2016, 57, 61-68.	3.0	33
29	Upregulation of Antioxidant Enzymes by <sc>ASS</sc>234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy. CNS Neuroscience and Therapeutics, 2016, 22, 799-802.	3.9	11
30	Wnt Signaling Pathway, a Potential Target for Alzheimer's Disease Treatment, is Activated by a Novel Multitarget Compound <sc>ASS</sc>234. CNS Neuroscience and Therapeutics, 2014, 20, 568-570.	3.9	19
31	A review of metalâ€catalyzed molecular damage: protection by melatonin. Journal of Pineal Research, 2014, 56, 343-370.	7.4	145
32	Melatonin as potential candidate to prevent the toxicity induced by chemical warfare agents. Archives of Toxicology, 2014, 88, 3-4.	4.2	34
33	The food contaminants aflatoxin B1, fumonisin B1, ocratoxina, T-2 toxin and deoxynivalenol decrease intestinal barrier permeability in human Caco-2 cells. Protector role of clay additives. Toxicology Letters, 2014, 229, S170.	0.8	0
34	In vitro relative potency of Type II pyrethroids and mixture dose-effects on oxidative stress cytotoxicity in SH-SY5Y, HepG2 and Caco-2 human cell lines. Toxicology Letters, 2014, 229, S45.	0.8	0
35	Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrine {11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 74, 491-501.	5.5	44
36	Toxicity induced by chemical warfare agents: Insights on the protective role of melatonin. Chemico-Biological Interactions, 2013, 206, 134-142.	4.0	12

#	ARTICLE	IF	CITATIONS
37	Cytotoxicity induced by deltamethrin and its metabolites in SH-SY5Y cells can be differentially prevented by selected antioxidants. <i>Toxicology in Vitro</i> , 2012, 26, 823-830.	2.4	63
38	Plasma disposition and tissue depletion of chlortetracycline in the food producing animals, chickens for fattening. <i>Food and Chemical Toxicology</i> , 2012, 50, 2714-2721.	3.6	20
39	Transfer of drugs and xenobiotics through milk. , 2011, , 57-71.		7
40	A 4-Week Repeated Oral Dose Toxicity Study of Dairy Fat Naturally Enriched in Vaccenic, Rumenic and $\hat{\pm}$ -Linolenic Acids in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2011, 59, 8036-8046.	5.2	15
41	Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening. <i>Food and Chemical Toxicology</i> , 2011, 49, 441-449.	3.6	20
42	Acute and Repeated Dose (28 Days) Oral Safety Studies of an Alkoxyglycerol Extract from Shark Liver Oil in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 2040-2046.	5.2	6
43	Acute oral safety study of dairy fat rich in trans-10 C18:1 versus vaccenic plus conjugated linoleic acid in rats. <i>Food and Chemical Toxicology</i> , 2010, 48, 591-598.	3.6	26